Literature DB >> 6652051

Prolonged heparin therapy in pregnancy causes bone demineralization.

M de Swiet, P D Ward, J Fidler, A Horsman, D Katz, E Letsky, M Peacock, P H Wise.   

Abstract

The relation of heparin therapy to osteoporosis was assessed in a retrospective analysis of 20 women treated during and after pregnancy with subcutaneous heparin for thromboembolism prophylaxis. The phalangeal cortical area ratio was significantly less after long term therapy (greater than 25 weeks) compared with that after short term therapy (less than 7 weeks). The same trend was found in the metacarpal area ratio, although this did not reach statistical significance. The changes were most marked in a woman who had received heparin also in a previous pregnancy. No correlations were found between duration of therapy and back pain, conventional radiology of lumbar spine or the Singh index of femoral trabecular pattern which were within the normal range in all patients. The findings indicate a dose-related demineralization process associated with prophylactic heparin therapy in pregnancy. The correct methods of and criteria for thromboembolism prophylaxis in pregnancy need critical re-examination.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6652051     DOI: 10.1111/j.1471-0528.1983.tb06459.x

Source DB:  PubMed          Journal:  Br J Obstet Gynaecol        ISSN: 0306-5456


  11 in total

Review 1.  Impact of bone mineral measurements on osteoporosis.

Authors:  I Fogelman; A Rodin; G Blake
Journal:  Eur J Nucl Med       Date:  1990

2.  Bone densitometry in clinical practice. Is indicated after long term treatment with heparin.

Authors:  C Nelson-Piercy; M De Swiet
Journal:  BMJ       Date:  1995-09-09

Review 3.  Adverse bone effects of medications used to treat non-skeletal disorders.

Authors:  N B Watts
Journal:  Osteoporos Int       Date:  2017-07-27       Impact factor: 4.507

Review 4.  Optimum use of anticoagulants in pregnancy.

Authors:  J S Ginsberg; J Hirsh
Journal:  Drugs       Date:  1988-10       Impact factor: 9.546

5.  The British Society for Haematology Guidelines on the use and monitoring of heparin 1992: second revision. BCSH Haemostasis and Thrombosis Task Force.

Authors:  B T Colvin; T W Barrowcliffe
Journal:  J Clin Pathol       Date:  1993-02       Impact factor: 3.411

Review 6.  The osteoporosis of heparinotherapy and systemic mastocytosis.

Authors:  T Bardin; M Lequesne
Journal:  Clin Rheumatol       Date:  1989-06       Impact factor: 2.980

7.  Guidelines on the prevention, investigation and management of thrombosis associated with pregnancy. Maternal and Neonatal haemostasis Working Party of the Haemostasis and Thrombosis Task.

Authors: 
Journal:  J Clin Pathol       Date:  1993-06       Impact factor: 3.411

8.  Effects of short-term, high dose, heparin therapy on biochemical markers of bone metabolism.

Authors:  F Cantini; L Niccoli; F Bellandi; O Di Munno
Journal:  Clin Rheumatol       Date:  1995-11       Impact factor: 2.980

9.  Effects of heparin, histamine, and salmon calcitonin on mouse calvarial bone resorption.

Authors:  A J Crisp; J K Wright; B L Hazleman
Journal:  Ann Rheum Dis       Date:  1986-05       Impact factor: 19.103

Review 10.  Long-term anticoagulation. Indications and management.

Authors:  B M Stults; W H Dere; T H Caine
Journal:  West J Med       Date:  1989-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.